---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-064467"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:14:31.238748+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals regains Nasdaq compliance with stockholders' equity requirement after $3.6M offering

## Summary
- Nasdaq confirmed compliance with Listing Rule 5550(b)(1) as of July 14, 2025.
- Deficiency arose from $2.13M equity as of Mar 31, 2025, below $2.5M minimum.
- June 2025 best-efforts offering raised ~$3.6M gross via shares and warrants.
- Nasdaq will monitor ongoing compliance; next periodic report may trigger re-evaluation.

## SEC filing metadata
- accession: 0001213900-25-064467
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390025064467/0001213900-25-064467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390025064467/ea0249089-8k_adial.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-064467
- JSON: https://secwatch.observer/filing/0001213900-25-064467.json
- Plain text: https://secwatch.observer/filing/0001213900-25-064467.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.